Literature DB >> 30483976

Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.

Masanori Oshi1, Georgios Antonios Margonis2, Yu Sawada1, Nikolaos Andreatos2, Jin He2, Takafumi Kumamoto1, Daisuke Morioka1, Christopher Lee Wolfgang2, Kuniya Tanaka1, Matthew John Weiss2, Itaru Endo3.   

Abstract

OBJECTIVE: The aim of this study was to examine if the prognostic significance of margin status in hepatectomy for colorectal cancer liver metastasis (CRLM) varies for different levels of tumor burden because hepatectomy indications for CRLM have been recently expanded to include patients with a higher tumor burden in whom achieving an R0 resection is difficult.
METHODS: Clinicopathological variables in an exploration cohort of 290 patients receiving hepatectomy in Japan for CRLM were investigated. R0 resection was defined as a margin width > 0 mm. Tumor burden was assessed using the recently introduced Tumor Burden Score (TBS), which was calculated as TBS2 = (maximum tumor diameter in cm)2 + (number of lesions)2. The principal findings were validated using a cohort from the United States.
RESULTS: R1 resection rates significantly increased as TBS increased: 4/86 (4.7%) in patients with TBS < 3, 29/171 (17.0%) in patients with TBS ≥ 3 and < 9, and 9/33 (27.3%) in patients with TBS ≥ 9 (p < 0.001). R0 resection was significantly superior to R1 resection in patients with TBS ≥ 5; however, this was not the case for TBS ≥ 6, as confirmed by both univariate and multivariate analyses. Furthermore, prehepatectomy chemotherapy was associated with significantly improved survival for patients with TBS ≥ 8. Analysis of the validation cohort yielded similar results.
CONCLUSIONS: R0 resection appeared to have a positive impact on prognosis among patients with low tumor burden; however, this was not the case for patients with high tumor burden. As such, systemic treatment, in addition to surgery, may be central to achieving satisfactory outcomes in the latter patient population.

Entities:  

Mesh:

Year:  2018        PMID: 30483976     DOI: 10.1245/s10434-018-6830-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review.

Authors:  Georgios Antonios Margonis; Martin E Kreis; Jaeyun Jane Wang; Carsten Kamphues; Christopher L Wolfgang; Matthew J Weiss
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

2.  Small-size (40 µm) Beads Loaded with Irinotecan in the Treatment of Patients with Colorectal Liver Metastases.

Authors:  Giovanni Mauri; Duccio Rossi; Samuele Frassoni; Guido Bonomo; Nicola Camisassi; Paolo Della Vigna; Vincenzo Bagnardi; Daniele Maiettini; Gianluca Maria Varano; Maria Giulia Zampino; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-14       Impact factor: 2.740

3.  Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis.

Authors:  Jiefeng Zhao; Jinfeng Zhu; Rui Sun; Chao Huang; Rongfa Yuan; Zhengming Zhu
Journal:  BMC Cancer       Date:  2021-05-06       Impact factor: 4.430

4.  Retrospective cohort study of statin therapy effect on resected colorectal liver metastases.

Authors:  Edward Alabraba; Hussain Ibrahim; Adina Olaru; Iain Cameron; Dhanny Gomez; Nottingham Hpb Surgery Group
Journal:  World J Gastrointest Surg       Date:  2020-02-27

5.  Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.

Authors:  Jianhong Peng; Yujun Liu; Weihao Li; Yuzhu Lin; Hui Sun; Zhizhong Pan; Xiaojun Wu; Wenhua Fan; Junzhong Lin
Journal:  Therap Adv Gastroenterol       Date:  2021-12-19       Impact factor: 4.409

6.  Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.

Authors:  Erman Aytaç; Leyla Özer; Bilgi Baca; Emre Balık; Yersu Kapran; Orhun Cığ Taşkın; Başak Oyan Uluç; Mehmet Ufuk Abacıoğlu; Murat Gönenç; Yasemin Bölükbaşı; Barbaros E Çil; Bülent Baran; Cem Aygün; Mehmet Erdem Yıldız; Kemal Ünal; Burçak Erkol; Tunç Yaltı; Uğur Özbek; Tan Attila; Nurdan Tözün; Bengi Gürses; Sibel Erdamar; Özlem Er; Nuran Beşe; Orhan Bilge; Güralp Onur Ceyhan; Nil Molinas Mandel; Uğur Selek; Cengiz Yakıcıer; Hülya Kayserili Karabey; Murat Saruç; Volkan Özben; Eren Esen; Emre Özoran; Erkan Vardareli; Levent Güner; İsmail Hamzaoğlu; Dursun Buğra; Tayfun Karahasanoğlu; The İstanbul Group
Journal:  Turk J Gastroenterol       Date:  2022-08       Impact factor: 1.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.